Cannabis Stocks Continue to Sell Off: Do Investors Need to Be Worried?

With cannabis stocks like Aurora Cannabis Inc (TSX:ACB)(NYSE:ACB) recording some of their worst losses in recent memory, is it a sign that the rally in cannabis stocks may finally be coming to an end?

Economic Turbulence

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Cannabis stocks are suffering their worst losses since late 2018, including shares of leading companies like Canopy Growth and Aurora Cannabis posting double-digit percentage declines so far through the month of July.

Meanwhile, HORIZNS MARIJUANA ETF isn’t faring a whole lot better. It’s also down just shy of 10% for the month.

Given the meteoric rise in pot stocks over the past couple of years, is last week’s sell-off perhaps a warning sign that the rally in licensed cannabis producers is finally over?

It’s difficult to say, because there is still so much that we don’t know about how cannabis markets will eventually play themselves out.

For starters, Canada at present is still only one of two countries where cannabis can legally be bought and sold, along with Uruguay, which first legalized recreational cannabis for sale and consumption back in 2013.

In Georgia and South Africa, possession of cannabis for recreational purposes is legal, but the sale of the drug is still prohibited.

Other G-20 nations like Australia, Germany, and Israel, meanwhile, have begun to gradually roll out legalized medicinal markets for pot but appear to remain years behind where Canada is today.

The red herring in all of this, of course, is the United States market.

Recreational pot is now legal across 11 states in the U.S., including Illinois, which has so far decriminalized the drug, but with official legalization not expected to come into effect until January 1, 2020.

The United States in December passed the Farm Bill Act, which, among other initiatives, formally lifted the ban on the cultivation of industrial hemp — a move that could eventually pave the way towards greater demand for CBD-related products, purported to offer many of the same medicinal properties as the cannabis plant, but without any of the unnecessary psychoactive by-products.

Cannabis bulls will certainly be hoping that the U.S. feds adopt a more liberal policy towards legalization, as not only does the U.S. market represent a significantly larger opportunity, but it could also pave the way for other major developed nations to loosen their own policies as well.

Ultimately, that could lead to a massive expansion in the size of the available market for pot and potentially even pot market derivatives.

While experts had originally forecast that the size of the legal Canadian market for cannabis would end up being somewhere between $5 billion and $10 billion in sales annually, industry pundits are now forecasting that the market for cannabis globally could reach as high as $250 billion in annual revenues.

Foolish bottom line

While those types of forecasts will certainly be the type to get the bulls’ mouths salivating, one can also be sure that American (and other nations) business interests will be eager to secure their own share of the proverbial “pot pie.”

With valuations already stretched, Canadian cannabis investors may want to tread carefully in light of the current sell-off that we’re seeing right now, despite that there appear to be several interesting opportunities still available within the space.

Making the world smarter, happier, and richer.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Jason Phillips has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »